Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Takeda Pharmaceutical Company Limited
< Previous
1
2
3
4
5
Next >
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
August 07, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
July 31, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces New Assignments of Directors
June 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
June 24, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
June 22, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
June 21, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
June 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
June 17, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
June 14, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
June 11, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
June 03, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
June 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
PFE
TAK
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
May 31, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
May 14, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
ACIU
TAK
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
May 09, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
April 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
April 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
April 08, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
March 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
March 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
March 19, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
March 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
February 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
February 12, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
February 08, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Chief Financial Officer Succession
February 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
February 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Tickers
TAK
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.